Effects of Lactobacillus plantarum CJLP133 on pediatric atopic dermatitis: a double-blind placebo controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000358

Enrollment

150

Registered

2012-02-10

Start date

2010-07-09

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : At the end of the initial 2-week placebo washout period, patients will be given either L. plantarum CJLP133 at a dosage of 0.5 × 10^10 colony forming units twice a day or the placebo preparat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged between 12 months and 13 years presenting atopic dermatitis will be enrolled. The diagnosis of atopic dermatitis is based on the criteria defined by Hanifin and Rajka. The criteria included a SCORAD index between 20 and 50. No other systemic illnesses or history of other probiotics during the past 4 weeks were included in the study.

Exclusion criteria

Exclusion criteria: 1) SCORAD score > 50 2) administration of immunosuppressant in the previous 3 months 3) administration of systemic corticosteroids or phototherapy in the previous 1 month 4) concomitant other skin diseases 5) administration of probiotics for a week or more in the previous 1 month 6) Principal investigator's decision that the patient is impossible to participate in the study

Design outcomes

Primary

Measure	Time frame
SCORAD (SCORing of Atopic Dermatitis) score	—

Secondary

Measure	Time frame
eosinophil;total IgE;cytokine (IL-4, IFN-?, TNF-a, TARC, CTACK)	—

Countries

Korea, Republic of

Contacts

Public ContactJihyun Kim

Samsung Medical Center

Outcome results